You just read:

Quest Diagnostics Introduces Dako's PD-L1 Complementary Diagnostic Test to Support Bristol-Myers Squibb's OPDIVO® Anti-PD-1 Therapy for Non-squamous Non-small Cell Lung Cancer

News provided by

Quest Diagnostics

Oct 09, 2015, 06:28 ET